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Purpose: The aim of this study was to evaluate complications in
patients with head and neck venous malformations (VMs) treated
with foam sclerotherapy using sodium tetradecyl sulfate (STS).
Methods: The authors retrospectively evaluated the complications,
pain. and degree of satisfaction in 69 consecutive patients affected
by cervicofacial VMmanaged with STS using the Tessari method in
a single institution.
Results: The average number of procedures for each patient was
2.1. The most frequent complication was blistering. We observed
1 patient of temporary weakness of a facial nerve branch, 1 para-
doxical embolism, and 1 orbital compartment syndrome.
The average pain score was 0 (no pain at all) (51.5%). There was
no statistically significant correlation between patient satisfaction
and the presence of complications or the degree of pain.
Conclusions: Sclerotherapy with STS is an effective treatment that
yields to very high patient satisfaction. This procedure has an overall
low complication rate and is usually effective within a few sessions.
However, severe complicationsmay occur; thesemust be pointed out
in the informed consent and the surgeon must be aware of and ready
to quickly treat them to prevent long-term sequelae.
Key Words: complication, endovascular, sclerotherapy, sodium
tetradecyl sulfate, vascular malformation, venous malformation
V ascular malformations are developmental abnormalities of thevascular tree present from birth. They are classified based on
the vessel type (capillary, venous, lymphatic, and arteriovenous) or
on their rheologic characteristics (slow-flow or fast-flow).1 Venous
malformations (VMs) are the most common vascular malformation,
and their treatment remains very challenging.2 Forty percent to 60%
of all VMs involve the head and neck area. Symptoms may vary and
include cosmetic complaints, pain, swelling, and functional limita-
tions. Frequently, localized intravascular coagulopathy3–5 can take
place in larger VMs and will worsen signs and symptoms. In more
‘‘benign’’ patients, symptoms can be so mild that no treatment is
needed, with the exception of conservative measures; in other
patient, symptoms are so severe that >1 treatment can be needed
and the approach has to be increasingly invasive.6–8
There are several options to treat VMs and these include
sclerotherapy, surgery, or laser.9 Overall, many descriptive studies
are present in the literature regarding sclerotherapy. However, most
focus on technical procedural aspects or short-term results only. The
conclusion in many articles is that VMs are difficult to treat and that
most patients require multiple therapeutic sessions before a clini-
cally relevant effect is obtained.
Many sclerosants such as ethanol, jellified ethanol, bleomycin,
polidocanol, or sodium tetradecyl sulfate (STS) are available, and
they show an effectiveness of 74%, 89%, 88%, 90%, and 86%,
respectively, according to a recent analysis.6
Ethanol is one of the most commonly used, and is a potent agent
for all types of vascular malformations. It provokes a denudation of
the intima layer by causing the death of endothelium. This distress
produces an immediate coagulation and thrombosis that can lead to
complete obliteration of vessel lumen. Differently from other scler-
osants, ethanol sclerotherapy is affected by a very low rate of
recanalization, which reflects a good long-term outcome. However,
ethanol is hampered by major side effect, such as relevant skin,
mucosal ormuscle necrosis, nerve injury, and systemic complications
including pulmonary hypertension, cardiovascular collapse, and
death 10–12 Instead, sclerotherapywith othermilder sclerosing agents
is recognized as a ‘‘safer’’ technique. Being much less painful, it can
also be performed under local anaesthesia (ethanol invariably
requires general anaesthesia), in an outpatient setting. From a cost/
benefit ratio point of view, the drug of choice seems to be STS.6
The aim of this study is to analyze the complications occurred on
69 consecutive patients with head and neck venous malformations
that were treated with endovascular injection of STS with the
Tessari method.13
MATERIALS AND METHODS
We retrospectively reviewed medical records and imaging of patients
diagnosed as having VM and treated with STS sclerotherapy during
the period 2011 through 2015 in a single institution. Being this a
retrospective study, an institutional review board was not required.
VMs were diagnosed with clinical examination and trough imaging
techniques (ultrasound and magnetic resonance imaging). Inclusion
criteria were: a diagnosis of head and neck VM; having received
sclerotherapy to treat the VM; having used STS as a sclerosant.
Exclusion criteria were: the VM being in a region different from the
head and neck; the VM being treated with means other than scler-
otherapy (surgery, laser); having used a sclerosant other than STS.
Sixty-nine patients were enrolled (average age 34). Overall, a total of
148 sessions (average: 2.1, range: 1–6) of sclerotherapy were per-
formed. Sclerotherapy was performed with STS adhering to the
Tessari method. In detail, 0.5 to 15 mL of sclerosant was injected
as foam with air in a 1:2 to 1:3 ratio. The clinical records of all 69
patients were reviewed to collect data to investigate whether a
complication occurred and, if so, what kind. Then all 69 patients
were contacted for a telephone interview. However, only 66
responded. In this latter, we investigated any residual sequelae and
the degree of patient satisfaction. The patients were asked whether
they considered the result good enough and whether he or she would
accept to undergo the same procedure again.
Univariate analyses were performed to determinate the inci-
dence of complications after sclerotherapy, the association between
the number of treatments, the type of complications occurred, and
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the patients’ satisfaction. Chi-squared test was performed to find out
correlation between type of complication and patients’ satisfaction.
We used Linear Regression Model to validate our results. All
statistical analyses were performed using SPSS software version
20.0 (IBM Corp, Armonk, NY).
Ethical Approval
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Informed consent was obtained from all individual participants
included in the study.
RESULTS
Number of Procedures
Thirty-three (47.8%) patients underwent 1 procedure, 12
(17.4%) underwent 2 procedures, 13 (18.8%) underwent 3 pro-
cedures, 5 (7.3%) underwent 4 procedures, 4 (5.8%) underwent 5
procedures, and 2 (2.9) underwent 6 procedures.
Complications
Frequent Complications
Of the 69 patients, 25 (36.2%) had blistering (Fig. 1), 11 (15.9%)
patients had minor ulceration (Fig. 2), and 8 (11.6%) had minor
bleeding on the site of the procedure. Sixteen (23.2%) patients had
limited movements (facial expression or mouth opening) owing to
oedema. Sixty-six patients responded to the phone interview. In a
scale factor from 0 to 5, 34 (51.5%) patients declared that the pain
was 0, 11 (16,7%) patients declared that the pain was 2, 4 (6,1%)
patients declared that the pain was 3, 9 (13,6%) patients declared
that the pain was 4, and 7 (10.6) patients declared that the pain was
5. None of them declared that the pain was 1.
Rare Complications
One patient (1.5% of patients, 0.6% of procedures) had a
temporary palsy of a buccal branch of the facial nerve (Fig. 3),
completely resolved after 6 months. This patient was treated for a
VM of the right masseter muscle (Fig. 4) with 1 cc of STS. One
patient (1.5% of patients, 0.6% of procedures) had a paradoxical
embolism, allowed by a patent foramen ovale. The patient presented
dysarthria and dysmetria, which resolved in few weeks. She was
treated with 10 cc of STS for a large cervicofacial VM. A detailed
description of this case was published previously.14 One patient
(1.5% of patients, 0.6% of procedures) had an orbital compartment
syndrome. This patient was treated with 10 cc of STS for a VM
occupying the right cheek, upper and lower lip, the hard and soft
palate, and the pharynx (Fig. 5). During the procedure, under
fluoroscopic guidance, a very small amount of sclerosant appeared
to ‘‘leak’’ into the orbital fraction of the VM. The procedure was
FIGURE 1. Very typical blistering occurring after foam sclerotherapy of left chin-
cheek venous malformation.
FIGURE 2. Mucosal necrosis of the lower lip few days after treatment of a
venous malformation infiltrating the mucosa.
FIGURE 3. Transient paresis of a buccal branch of the right facial nerve after
treatment of a venous malformation of the right masseter muscle.
FIGURE 4. Magnetic resonance imagong of patient depicted in Fig. 3 showing
a venous malformation within the lateral margin of the right masseter muscle
(arrow).
FIGURE 5. Preoperative magnetic resonance imaging of a vast venous
malformation of the right face involving the cheek, the palate and the orbit.
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immediately interrupted at this point. However, in the observation
room, 20minutes after the procedure, the swelling progressively
increased (Figs. 6 and 7). A bolus with 40-mg dexamethasone did
not stop the event. For this reason, the patient underwent a bedside
canthotomy and cantholysis (Fig. 8) and then, under general
anaesthesia, a decompression by means of a lateral orbital wall
osteotomy was performed (Fig. 9). Visual acuity was preserved.
Ten days after, the patient was operated on again and the bony wall
was repositioned and stabilized with titanium plates and screws.
There was no procedure-related mortality (Fig. 10).
Patient Satisfaction
Fifty-two (78.8%) patients declared that they have reached the
desired result and that they would undergo another similar pro-
cedure, stressing the high satisfaction rate. There was no correlation
between the satisfaction and the type or the severity of the com-
plication (P¼ 0.336) or the pain level (P¼ 0.245).
DISCUSSION
There is a general agreement on the fact that sclerotherapy should
be the first-line treatment for clinically relevant VMs.15 Many
different sclerosants have been used for this purpose. A systematic
analysis on different available sclerosants is beyond the scope of
this article. Ethanol is known as the most powerful sclerosing agent
and it has been considered the criterion standard for years. It
possesses the highest endothelial-cydal effectiveness and it causes
a complete thrombosis of the vessel lumen. However, ethanol is also
known for causing a high rate of major complications such as skin or
subcutaneous tissue breakdown, nerve damage, muscle necrosis,
and systemic complications including pulmonary hypertension,
cardiovascular collapse, and death.10 Moreover, severe pain is
perceived by the patient during injection of pure ethanol. For this
reason, sclerotherapy with ethanol requires general anesthesia with
constant vital signs monitoring and should be performed only in
centers with very high professional expertise. Some authors recom-
mend 24 hours of intensive care unit monitoring after a session of
ethanol sclerotherapy.16 The use of ethanol for sclerotherapy may
however be preferred in some centers owing to its lower cost and
availability.17 Still, the rate of disease recurrence seems to be the
lowest among sclerosing agents.18,19 However, sclerotherapy per-
formed with STS has a much lower rate of complications, but could
be less effective and more treatment session could be needed.20
Sclerotherapy with STS can be performed safely on an outpatient
basis. STS can be used both as a pure liquid sclerosant or as a foam
with air with the Tessari method.13 Van der Vleuten et al6 assert that
the choice of treatment (between sclerotherapy, surgery and laser
therapy) is a shared decision between the patient and a multi-
disciplinary treatment group and that, from a cost perspective,
sclerotherapy with STS should be the treatment of choice. Scler-
otherapy should be in any case the first-line treatment.15,21
Comparison of This Case Series With Other
Published Results
The first discrepancy that is noted is that the average number of
sessions performed in our cohort was 2.1, which is lower than an
average 2.63 found in a review of the literature focusing on ethanol
sclerotherapy of VMs.22 The reason behind this could be the fact
FIGURE 6. Twenty minutes after injecting the sclerosant, a right compartment
syndrome took place. Note the severe proptosis of the right eye.
FIGURE 7. Computed tomography scan of the patient depicted in Fig. 6. Note
the proptosis of the right eye and the presence, within the right orbit, of gas
bubbles testifying the leakage of foam sclerosant in the orbital fraction of the
venous malformation.
FIGURE 8. Bedside canthotomy and cantholysis.
FIGURE 9. Lateral orbital wall osteotomy and lateral displacement to
decompress the orbit.
FIGURE 10. Postoperative appearance of patient depicted in Figs. 5–9.
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that the average follow-up of this case series is just 2 years and we
could face relapses needing further treatment.
Analysis of Complications
The most frequent complication was blistering, and this is coher-
ent with other reports. Ulceration, on the contrary, was more frequent
in our case series than on average. The reason behind this could be the
fact thatwehave treated patients affectedbyhead andneckVMsonly.
Here, oral involvement is almost invariably jeopardized by ulceration
if the VM infiltrates the mucosa. Edema, causing impaired facial
expression and mouth opening was the rule when major VMs of the
face were treated. Swelling though should not be regarded as a
complication but rather as a very reliable sign of long-term treatment
effectiveness.23 Pain was a relatively minor issue. Most patients say
they did not feel pain at all. However, an overall 25.7% of patients
reported a high or very high degree of pain during or after the
procedure. Still, even these patients declared that they would accept
to undergo the same procedure if needed and this underlines a very
high degree of acceptance of the procedure by the patients. There
were, although only episodically, major complications.
Nerve Impairment
We have observed 1 patient of temporary weakness of a buccal
branch of the facial nerve. Peripheral nerve injury after ethanol
sclerotherapy is a known complication. However, even with STS
transient or permanent nerve impairment can happen. In a recent
retrospective analysis of 204 patients, Stuart et al24 reported 7
patients of transient and/or permanent nerve dysfunction. This
means an average 3.4%. We had just 1 patient (2%) of transient
nerve damage, which is lower. However, the same authors observed
3 patients of permanent injury (1.5%), whereas we had none.
Detergents are not intrinsically neurotoxic, so the pathophysiology
should be explained differently. A damage to the ‘‘vasa nervorum’’
or an indirect injury caused by intense swelling or by extravasation
of the sclerosant causing tissue necrosis could be hypothesized. It is
important, however, to underline the fact that there is no study in
literature that focuses on complications after sclerotherapy with
ethanol of VMs involving just head and neck region.
Orbital Compartment Syndrome
One patient suffered from intense swelling of the right orbit after
injecting a palatal VM. In the literature, there is another report of a
patient who lost sight after sclerosing a vast facial VM involving the
orbit.25 When a sclerosant reaches part of a VM inside the orbit, a
compartment syndrome can be predicted. This must be treated in
the same way a retrobulbar hemorrhage would be managed.
Prompt administration of high doses of steroids, bedside canthot-
omy and cantholysis and, if needed, lateral and/or medial wall
decompression, must be carried out within 120minutes to pre-
serve sight.26,27
We observed 1 (2%) paradoxical embolism,14 because of a
patent foramen ovale. This is a very rare complication; according
to a 2012 review28 from 1994 to 2014, there have been only 13
published patients of paradoxical embolism, and in most patients, a
patent foramen ovale was present. The procedure is very frequent
and this complication is very rare; therefore, a preoperative echo-
cardiographic study is theoretically not indicated.
The majority of patients would undergo again similar treat-
ments; this underlines how patient satisfaction is very high. In
addition, according to the statistical analysis, the satisfaction of the
patient is not in any way affected by the presence of complications.
No type of complication is indeed correlated with the degree of
patient satisfaction. Probably the satisfaction of the patient is
correlated with the effectiveness of the procedure, especially in
case of venous malformations localized at the level of the head &
neck, where the aesthetic aspect is undoubtedly important, owing to
the fact that the lesions cannot be hidden.
CONCLUSION
Foam sclerotherapy with STS confirms to be a very well tolerated
procedure. It should be noted though that major complications can
occur, especially when dealing with major VMs. For these reasons,
it is imperative that this particular cohort of patients is treated in a
highly protected setting, where emergent procedures can be readily
adopted to protect the airways or the orbital content. Although the
patient who had paradoxical embolism eventually healed without
consequences, the likelihood of this event must be discussed with
patients having large VMs and in these patients we prefer to have a
preoperative trans oesophageal ultrasound examination excluding
right to left shunts.
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Botulinum Toxin Conjugated
With Silk Fibroin and
4-Hexylresorcinol
You-Young Jo, PhD, Seong-Gon Kim, PhD,y
and Min-Keun Kim, DDS, MSDy
Purpose: The objective of this study was to evaluate whether silk
fibroin (SF) incorporated into 4-hexylresorcinol (4HR) could
increase botulinum toxin-A (BTX-A) activity.
Material and methods: In total, 30 rats were used for this study.
The animals were divided into 6 groups according to the injected
materials (SA: saline only; SF; 4HR; B2: 2 units of BTX-A;
B2þSFþ 4HR: combination of B2, SF, and 4HR; B5: 5 units
of BTX-A). Serial sonography was used for the evaluation of
muscle thickness after injection. Immunohistochemical staining
was used for the evaluation of myosin type II (myo2) and Bcl-2
protein expression.
Results: The relative thickness of the masseter muscle in B2 group
was 66.14% 4.55% to the preinjection level; in B2þSFþ 4HR
group was 54.59% 4.83%, and in B5 group was 56.19% 8.28%.
Any BTX-injected group showed significantly lower value of the
relative muscle thickness compared to SA, SF, or 4HR group
(P< 0.001 for all). The difference of relative muscle thickness
between B2 group and B2þ SFþ 4HR group was statistically
significant (P< 0.001). The intensity of myo2 immunostaining
in B5, B2, and B2þ SFþ 4HR group was significantly higher than
those in the other groups (P< 0.05).
Conclusions: When 2 units of BTX was incorporated to SF and
4HR, combination formula showed similar activity to those of 5
units of BTX.
Key Words: 4-Hexylresorcinol, botulinum toxin, silk fibroin
B otulinum toxin (BTX) is a neurotoxin and mainly blocks theneurotransmission of cholinergic nerve.1 There are several
subtypes of BTX.1 BTX-A has been mainly used in clinical fields.2
BTX-A has been used for the correction of facial esthetics3 and
the treatment of temporomandibular disorder.4 As the cholinergic
nerve innervates into salivary gland, BTX-A injection can be
considered for the correction of Frey syndrome5 and hypersaliva-
tion.6 BTX-A therapy also has been used for the correction of post-
traumatic open-bite.7 As the indication for BTX-A injection has
been widen rapidly, the usage of BTX-A will be increased
accordingly.
BTX is composed of heavy chain (100 kDa) and light chain
(50 kDa).8 Between 2 components, several disulfide bonds are
found.8 As free form of BTX is fragile to the attack of protease
and low pH, bacteria produces BTX as a high molecular weight of
progenitor toxin complex containing protector protein.8 Therefore,
commercially available BTX-A is usually provided as freeze-dried
toxin with albumin as protector protein. After reconstitution with
normal saline, the manufacturer recommends that BTX-A should be
stored in refrigerator (28C–88C) and used as soon as possible.9
Storage beyond 4 hours after reconstitution has decreased the
efficacy of BTX-A.10,11 Some authors claimed that residual
BTX-A could be stored in room temperature for 4 months without
significant loss of activity.12 Generally, 2 weeks of storage in
refrigerator without freezing seems to be safe, not affecting the
efficacy of BTX-A.9,13 However, repeated usage of BTX-A after
reconstitution is not recommended by manufacturer because of
increased contamination risk.9 Commercially available BTX-A
is produced from bacteria or from eukaryotic cells. The price for
BTX-A is generally expensive.9
4-Hexylresorcinol (4HR) is a well known antiseptics14 and can
be used for the structural stabilization of protein.15,16 Low concen-
tration of 4HR can increase the activity of lysozyme.16 Therefore,
4HR may stabilize the structure of BTX-A and increase the activity
of BTX-A. Silk fibroin (SF) is produced by Bombyx mori and
considered as drug carrier.17 SF and 4HR combination has been
widely studied in tissue engineering for the development of soft
tissue augmentation material18 or membrane.19 4HR can influence
gene expression and protein function in cancer cells20 and macro-
phages.21 As the light chain of BTX has protease activity,8 4HR-
incorporated drug carrier may influence BTX activity.
The objective of this study was to evaluate that SF-conjugated
4HR could increase BTX-A activity. The serial sonography was
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